Pieris Pharmaceuticals (NASDAQ:PIRS) Coverage Initiated by Analysts at StockNews.com

StockNews.com began coverage on shares of Pieris Pharmaceuticals (NASDAQ:PIRS) in a research note released on Tuesday. The firm issued a hold rating on the biotechnology company’s stock.

Pieris Pharmaceuticals Trading Down 3.0 %

Shares of NASDAQ:PIRS opened at $8.96 on Tuesday. Pieris Pharmaceuticals has a 1-year low of $8.71 and a 1-year high of $41.78. The stock has a market capitalization of $11.83 million, a P/E ratio of -0.75 and a beta of 0.73. The business has a 50-day moving average price of $10.94 and a two-hundred day moving average price of $12.88.

Pieris Pharmaceuticals (NASDAQ:PIRS) last posted its quarterly earnings results on Wednesday, May 15th. The biotechnology company reported ($3.95) earnings per share for the quarter. Pieris Pharmaceuticals had a negative return on equity of 57.57% and a negative net margin of 39.71%. The business had revenue of $0.05 million for the quarter.

Institutional Investors Weigh In On Pieris Pharmaceuticals

A hedge fund recently bought a new stake in Pieris Pharmaceuticals stock. Summit Trail Advisors LLC bought a new stake in Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 140,000 shares of the biotechnology company’s stock, valued at approximately $26,000. Summit Trail Advisors LLC owned approximately 0.14% of Pieris Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission (SEC). 40.11% of the stock is owned by institutional investors and hedge funds.

About Pieris Pharmaceuticals

Pieris Pharmaceuticals, Inc, a biotechnology company, discovers and develops biotechnological applications. The company focuses on the development of its 4-1BB bispecifics immuno-oncology (IO) programs. Its clinical pipeline consists of IO bispecifics, including S095012 (PRS-344), a bispecific Mabcalin compound targeting PD-L1 and 4-1BB in partnership with Les Laboratoires Servier and Institut de Recherches Internationales Servier; SGN-BB228 (PRS-346), a CD228 x 4-1BB bispecific antibody-Anticalin compound targeting CD228 and 4-1BB in partnership with Pfizer Inc; and BOS-342 (PRS-342), a GPC3 x 4-1BB bispecific Mabcalin compound targeting GPC3 and 4-1BB in partnership with Boston Pharmaceuticals, which are in phase 1 studies.